By Chris Wack

Dyne Therapeutics shares were 7% higher, at $19.34, after the company said it entered into an amendment to its non-dilutive senior secured term loan facility with Hercules Capital.

The clinical-stage company said the transaction further strengthens its balance sheet as it advances zeleciment rostudirsen for exon 51 Duchenne muscular dystrophy and zeleciment basivarsen for myotonic dystrophy type 1.

Under the terms of the amendment, $50 million was funded upon execution of the amendment, and an additional term loan tranche for $50 million that can be drawn at Dyne's option subject to the achievement of certain milestones was added to the term loan facility.

The final term loan tranche was also increased by $25 million to provide up to an additional $75 million, which may be funded upon request of Dyne and at the discretion of Hercules Capital.

Dyne said that including the $50 million funded upon execution of the amendment, it has borrowed $200 million in loan proceeds in three tranches under the term loan facility and maintains access to up to $200 million in potential future funding under the facility.

Write to Chris Wack at chris.wack@wsj.com

(END) Dow Jones Newswires

June 17, 2026 10:16 ET (14:16 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.